MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

Irene M Ghobrial,David Siegel,Ravi Vij,Jeffrey L Wolf,Jesus G Berdeja,Jeffrey V Matous,Peter Lipman,Chirag Patel,Trinh Le,Christian Rommel,Gregory Berk

doi:10.1182/blood.v120.21.4038.4038

MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

Irene M Ghobrial, David Siegel + Show 9 more

https://doi.org/10.1182/blood.v120.21.4038.4038

Copy DOI

Journal: Blood	Publication Date: Nov 16, 2012
Citations: 4

Affiliation: Dana-Farber Cancer Institute, Hackensack University Medical Center, Washington University in St. Louis, University of California, San Francisco, Colorado Blood Cancer Institute, Millennium Engineering and Integration (United States), Intel (United States)

#Advisory Committees #Entity's Board + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

Full Text